Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

United Kingdom Clinical Study Demonstrates Aerocrine AB's FeNO Can Identify Non-Adherence to Medication


Monday, 17 Dec 2012 02:13am EST 

Aerocrine AB announced that clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is a tool to identify patients that do not adhere to treatment. The American Journal of Respiratory and Critical Care Medicine published on December 1, 2012 the results of a clinical study done at Queen's University in Belfast, Northern Ireland. The results show how fractional exhaled nitric oxide (FeNO) measurement is a tool for identifying patients who did not use their prescribed inhaled corticosteroids, i.e. did not adhere to treatment. Aerocrine's patented FeNO test, with the NIOX MINO device, was used in the study. The United Kingdom study is entitled: The Utility of Fractional Exhaled Nitric Oxide Suppression in Identification of Non-adherence in Difficult Asthma; its purpose was to identify a test for non-adherence using fractional exhaled nitric oxide (FeNO) suppression after directly observed inhaled corticosteroid treatment. The study concluded that the FeNO suppression test can identify whether or not patients use their inhaled corticosteroid therapy properly and if patients, who fill their prescriptions, took their medicine. Non-adherence is common and ranges from 35% to 65%. An editorial in the same journal stated that there are studies which suggest that FeNO measurements may be used to confirm non-adherence with inhaled corticosteroid therapy in children. But no study has investigated the same measurements in adults. 

Related Company News

Company Quote

4.47
-0.03 -0.67%
19 Sep 2014